2 results
Approved WMOCompleted
To assess the rates of preliminary response and sustained remission of AASV following rituximab (on the basis of former studies, 86% sustained remission expected with rituximab compared to 75% in control group).To assess safety of a rituximab…
Approved WMOCompleted
This study is being conducted to collect additional data to describe the safety and tolerability of multiple cycles of IV administration of fosaprepitant daily for 3 consecutive days, concomitantly with a 5-HT3 antagonist, with or without…